Trade Mark Journal No.2026/003 16 January 2026
WO0000001894108 (5,42)
Office of origin: France
Date of International Registration:5 November 2025
Date of designation in the UK:
5 November 2025
International priority date claimed: 6 May 2025
(France)
(5145173)
- Class 5
- Allogeneic or autologous cellular and molecular innovative therapy medications; pharmaceutical products for treating oncological diseases; pharmaceutical products for treating diseases of the immune system; pharmaceutical products for treating inflammatory diseases; pharmaceutical products for treating autoimmune diseases; immunomodulatory medicines; anti-inflammatory medicines; cellular-function activating agents for medical purposes; biological preparations for cancer treatment; biological preparations for medical use; biochemical preparations for medical use; biological tissue cultures for medical use; stem cells for use in cell and gene therapies; cell culture media for medical use.
- Class 42
- Research and development services for innovative solutions for allogeneic and autologous molecular and cellular therapy; design services for innovative solutions for allogeneic or autologous molecular and cellular therapy; medical and pharmacological research services; research and development in the field of stem cells, cell and gene therapy and biotechnology; providing scientific research information in the field of stem cells, cell and gene therapy and biotechnology; clinical trials; providing information concerning clinical trial results for pharmaceutical products in the field of autologous or allogeneic cellular and molecular therapy; technical project study services in the field of allogeneic or autologous cellular and molecular therapy; provision of information and data with respect to medical research and development.
THERALLO
Representative: BEACCO Marine ICOSA, 83 Avenue Denfert-Rochereau, F-75014 PARIS, FRANCE